First CD123-targeted drug approved after wowing in rare cancer. First CD123-targeted drug approved after wowing in rare cancer. Nature biotechnology Dolgin E. PMID: 30833771 Nat Biotechnol. 2019 Mar;37(3):202-203. doi: 10.1038/s41587-019-0056-8. No abstract available. Share Share on social media Direct link Direct link Cite Cite AMA Dolgin E. First CD123-targeted drug approved after wowing in rare cancer. Nat Biotechnol. 2019;37(3):202-203doi: 10.1038/s41587-019-0056-8. APA Dolgin, E. (2019). First CD123-targeted drug approved after wowing in rare cancer. Nature biotechnology, 37(3), 202-203. https://doi.org/10.1038/s41587-019-0056-8 MLA Dolgin, Elie. "First CD123-targeted drug approved after wowing in rare cancer." Nature biotechnology vol. 37,3 (2019): 202-203. doi: https://doi.org/10.1038/s41587-019-0056-8 NLM Dolgin E. First CD123-targeted drug approved after wowing in rare cancer. Nat Biotechnol. 2019 Mar;37(3):202-203. doi: 10.1038/s41587-019-0056-8. PMID: 30833771. Copy Download .nbib Format: NLM AMA APA MLA NLM
